جستجوی مقالات مرتبط با کلیدواژه « رژیم های دارویی » در نشریات گروه « پزشکی »

Four-drugs treatment included of Bismuth–Omperazole–Metronidazole and Amoxicillin have been used as first line treatment for Helicobacter Pylori eradication by many of physician in Iran. However, there is an uncertainty for effectiveness of the regime on patients of Hamadan with the resistance rate of this regime reported in different parts of the country. Present study attempt to evaluate the effectiveness of this regime as first line treatment of H. Pylori in patients of Hamadan.. There are 100 patients with recognized H.pylori infection who could terminate this study. At first, these patients treated by four-drugs regime for 2 weeks, then they treated with Omprazole for 1 month. Successful eradication was determined as negative Urease Test with Carbon 13. The average of individual ages was 38±11.78 years old. 57% of patients were men. The eradication rate of H.pylori was 80% and the eradication had no significant correlation with the age, gender, clinical symptoms and endoscopic findings. Four-drugs treatment included of Omperazole-Metronidazole-Amoxicillin and Bismuth is effective in patients of Hamadan and still could be applicable in H.pylori treatment as the first line treatment.

Background and Ëradication of Helicobacter pylori (H.pylori) is essential for the effective treatment of peptic ulcer (p.ulcer). Triple therapy as the first line of treatment in eradication of H.pylori is recommended. Ïn this study, we aimed at comparing the efficacy of quadruple and triple therapies containing low dose furazolidone versus a triple therapy containing metronidazole and bismute. Ïn this study, 150 patients under endoscopy who had deodenal ulcer and confirmed for H.pylori were randomly enrolled with one of the following three methods of ÔÂF omeprasol 20 mg BÏD, amoxycillin 1000 mg BÏD and furazolidone 100 mg BÏD or metronidazole 500 mg BÏD (ÔÂM) and/or (ÔÂBF), omeprazol 20 mg BÏD, amoxycillin 1000 mg BÏD, furazolidone 100 mg BÏD and bismuth subcitrate 240 mg BÏD for 2 weeks. Ëradication of H.pylori 12 weeks after treatment was assessed confirmed with 14-c urea breath test. 150 patients,included 88 males and 62 females with mean age group of 40.3 ± 11.5 were under study. Ïn these three groups, there was no significant difference for ratio of male to female, mean age, smoking, gastrointestinal bleeding history, using of non steroid drugs, duration of observing symptoms and size of ulcer. Drug compliance for ÔÂF, ÔÂM and ÔÂBF were 94%, 96% and 98% respectively. Severe side effects (malaise, anorexia and diarrhea) of ÔÂF were observed in 8%, in ÔÂM 4% (headache and dry mouth), in ÔÂBF group 6% (malaise, nausea and dizziness). 140 patients could complete the treatment courses. Rate of eradication based on intention to treat for ÔÂBF, ÔÂM and ÔÂF were 72%, 40% and 54% respectively, and based on completion of the study were 73.4%, 40.8% and 57.4% respectively. Çonclusion: Çonsidering the obtained result, and in spite of priority of Furazolidone, none of the three mentioned triple theray regimens had required efficacy and are not recommended for eradication of H.pylori. Ïn quaruple regimens containing low dose of furazolidone, eradication rate of H.pylori had significant increase, but was less than gold standard. Therefore in order to obtain ideal regimen, more study with low doses of furazolidone such as, moderate dose of furazolidone daily 300 mg in quadruple regimen for 2 weeks or even high dose of furazolidone 400 mg daily. Ïn quadruple regimen furazolidone only in the first week and rest of drugs, are recommended. for 2 weeks.